These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35514306)

  • 1. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
    Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
    Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
    J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
    Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
    EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Cheng SMS; Mok CKP; Leung YWY; Ng SS; Chan KCK; Ko FW; Chen C; Yiu K; Lam BHS; Lau EHY; Chan KKP; Luk LLH; Li JKC; Tsang LCH; Poon LLM; Hui DSC; Peiris M
    Nat Med; 2022 Mar; 28(3):486-489. PubMed ID: 35051989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
    Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
    EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
    Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
    Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
    Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
    Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022.
    Atari N; Kliker L; Zuckerman N; Elkader BA; Weiss-Ottolenghi Y; Mendelson E; Kreiss Y; Regev-Yochay G; Mandelboim M
    Euro Surveill; 2022 Nov; 27(44):. PubMed ID: 36330820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022.
    Kliker L; Zuckerman N; Atari N; Barda N; Gilboa M; Nemet I; Abd Elkader B; Fratty IS; Jaber H; Mendelson E; Alroy-Preis S; Kreiss Y; Regev-Yochay G; Mandelboim M
    Euro Surveill; 2022 Jul; 27(30):. PubMed ID: 35904058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
    Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
    Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
    Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
    Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.